1977PubMedRequires access

Efficacy of once-weekly isoniazid-streptomycin in preventing relapse of pulmonary tuberculosis.

O. Nazareth, R Parthasarathy, C. V. Ramakrishnan, T Santha, S. Sivasubramanian, P. R. Somasundaram, S. Subbammal, Srikanth Tripathy

Open publisher page 2 citations

Abstract

Two controlled studies were undertaken to assess the efficacy of streptomycin 1 g. or 0.75 g. (by random allocation) plus isoniazid 15 mg./kg. body-weight once-weekly (the SHOW regimen) in the prevention of bacteriological relapse over a 4 year period, in patients with quiescent pulmonary tuberculosis at the end of one year of chemotherapy. In the first study which involved patients with residual cavitation at one year, bacteriological relapse requiring treatment occurred in 3 per cent of 87 patients given the SHOW regimen for 12 months as compared with 21 per cent of 94 patients on a placebo, a high proportion of the relapses in the latter occurred in the 2nd year and with sensitive organisms. In the second study on patients with no residual cavitation at one year, relapse requiring treatment occurred in 2 per cent of 98 patients given the SHOW regimen for 6 months as compared with 1 per cent of 90 patients given isoniazid approximately 4.5 mg./kg. daily for 12 months.

About this research paper

What this paper is about

Two controlled studies were undertaken to assess the efficacy of streptomycin 1 g. or 0.75 g. (by random allocation) plus isoniazid 15 mg./kg. body-weight once-weekly (the SHOW regimen) in the prevention of bacteriological relapse over a 4 year period, in patients with quiescent pulmonary tuberculosis at the end of one year of chemotherapy. In the first study which involved patients with residual cavitation at one year, bacteriological relapse requiring treatment occurred in 3 per cent of 87 patients given the SHOW regimen for 12 months as compared with 21 per cent of 94 patients on a placebo, a high proportion of the relapses in the latter occurred in the 2nd year and with sensitive organisms. In the second study on patients with no residual cavitation at one year, relapse requiring treatment occurred in 2 per cent of 98 patients given the SHOW regimen for 6 months as compared with 1 per cent of 90 patients given isoniazid approximately 4.5 mg./kg. daily for 12 months.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Two controlled studies were undertaken to assess the efficacy of streptomycin 1 g. or 0.75 g. (by random allocation) plus isoniazid 15 mg./kg. body-weight once-weekly (the SHOW regimen) in the prevention of bacteriological relapse over a 4 year period, in patients with quiescent pulmonary tuberculosis at the end of one year of chemotherapy. In the first study which involved patients with residual cavitation at one year, bacteriological relapse requiring treatment occurred in 3 per cent of 87 patients given the SHOW regimen for 12 months as compared with 21 per cent of 94 patients on a placebo, a high proportion of the relapses in the latter occurred in the 2nd year and with sensitive organisms. In the second study on patients with no residual cavitation at one year, relapse requiring treatment occurred in 2 per cent of 98 patients given the SHOW regimen for 6 months as compared with 1 per cent of 90 patients given isoniazid approximately 4.5 mg./kg. daily for 12 months.

Key concepts: Isoniazid, Regimen, Streptomycin, Medicine, Placebo, Tuberculosis, Internal medicine, Pulmonary tuberculosis

Related papers

Back to paper searchBrowse research topicsOriginal source
Efficacy of once-weekly isoniazid-streptomycin in preventing relapse of pulmonary tuberculosis. — Research Paper | ScholarLens